Looking for a career in immunology? Look no further! Here are the top 5 pharmaceutical companies by revenue.
Immunology is the study of the immune system and its functions and disorders, and pharmaceutical companies play a critical role in developing and manufacturing drugs that help treat and manage these conditions. There are many different types of immune-related disorders, ranging from autoimmune diseases like rheumatoid arthritis and inflammatory to bowel diseases, allergies and infections.
If you're a pharmacist or a scientist looking for a rewarding and impactful career, joining a pharmaceutical company's immunology division might be the perfect choice for you. By developing and manufacturing drugs that treat immune-related disorders, you'll have the opportunity to make a real difference in the lives of patients and help alleviate suffering on a global scale. Moreover, working in immunology offers the chance to be at the forefront of scientific discovery and collaborate with a wide range of professionals. Without further notice, here are the top 5 immunology companies by revenue you would want to join as of 2023
AbbVie
AbbVie
The pharmaceutical giant from Chicago, USA, is the market leader that specialises in immunology. AbbVie has a robust portfolio of drugs to treat immune-related disorders. Their portfolio includes drugs like Humira, Skyrizi, and Rinvoq, among others, which are used to treat conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease, among others. Humira is one of AbbVie's most successful drugs and is the world's best-selling prescription medication. It is used to treat a variety of immune-related disorders, including rheumatoid arthritis, psoriasis, and Crohn's disease, among others. In 2020, Humira generated revenue of $19.8 billion for AbbVie. Skyrizi and Rinvoq are newer drugs in AbbVie's immunology portfolio. Skyrizi is used to treat psoriasis and generated revenue of $2.5 billion in 2020, while Rinvoq is used to treat rheumatoid arthritis and generated revenue of $2.1 billion in 2020. AbbVie is also investing heavily in research and development to expand its immunology portfolio and bring new drugs to the market. They have several drugs in the pipeline, including upadacitinib, which is being developed to treat several immune-related disorders, including rheumatoid arthritis and Crohn's disease.
Johnson & Johnson (Janssen)
Janssen Pharmaceuticals
Belgium subsidiary of Johnson & Johnson and its immunology division is one of the company's key focus areas. In 2020, Johnson & Johnson reported $45.6 billion in total revenue, with a significant portion of that coming from the sales of its immunology products. While Janssen's revenue is not reported separately from Johnson & Johnson, the company's immunology portfolio, which includes products such as Stelara, Remicade, and Simponi, has been a major contributor to Johnson & Johnson's overall revenue. In fact, Janssen's immunology products have consistently been among the top-selling drugs in the world despite the challenges posed by the COVID-19 pandemic.
Sanofi
Sanofi
At the time of writing, Sanofi is still a top 10 French company by market capitalisation. They have been performing strongly in challenging times. They offer a wide range of products, including some for immunology, such as Dupixent, Kevzara, and Sarilumab. These products have been helpful for people dealing with issues like rashes, swollen joints, and breathing problems. In fact, Sanofi made an impressive €36.1 billion in 2020, with a significant portion coming from the sale of their immunology products. It's encouraging to see that their immunology division is thriving and expected to continue to do so in the future.
Roche
Roche
Number four on our list is the Swiss multinational giant. Their portfolio crosses many areas, but their immunology portfolio includes well-established drugs such as Actemra, Esbriet, and Ocrevus, which are used to treat patients with conditions such as rheumatoid arthritis, pulmonary fibrosis, and multiple sclerosis. In 2020, Roche's global sales revenue was CHF 58.3 billion, with a significant portion coming from its pharmaceutical division. While Roche's immunology division is just one aspect of its overall business, it has contributed to its success and growth in recent years.
Novartis
Novartis
The second Swiss giant on our list is Novartis. Their immunology portfolio includes drugs such as Cosentyx, Ilaris, and Zolgensma, which are used to treat patients with conditions such as psoriasis, juvenile idiopathic arthritis, and spinal muscular atrophy. In 2022, Novartis reported a revenue of USD 7.29 billion in Immunology alone. Their pipeline is in dermatology, and rare diseases are exciting; the future looks bright for the company and the patients they serve.
Working in the immunology division of a top pharmaceutical company can be a highly rewarding and impactful career choice. By developing and manufacturing drugs that treat immune-related disorders, you'll have the opportunity to make a real difference in the lives of patients and help alleviate suffering on a global scale. The top 5 immunology companies by revenue, such as AbbVie, Johnson & Johnson, Sanofi, Roche, and Novartis, offer exciting opportunities to work with some of the most innovative and successful companies in the industry. With robust portfolios of drugs and strong revenue streams, these companies are investing heavily in research and development to expand their immunology division and bring new and innovative drugs to the market. If you're a pharmacist or a scientist looking for a rewarding career with the chance to make a difference, joining a top immunology company could be the perfect choice for you.
Thanks for reading until next time.